The Europe clinical trials market is expected to grow from US$ 15,739.35 million in 2022 to US$ 21,643.87 million by 2028. It is estimated to grow at a CAGR of 5.5% from 2022 to 2028.

Increasing Adoption and Outsourcing of Clinical Trials Fuels Europe Clinical Trials Market

Clinical trials are crucial for establishing the safety and efficacy of new treatments or preventative measures, such as novel drugs, diets, or medical devices. These trials are predominantly conducted during the drug development lifecycle. The European Medicine Agency indicates that about 4,000 clinical trials are authorized annually in the EU, with approximately 60% originating from the pharmaceutical industry. The market for clinical trials is experiencing growth due to the increasing number of trials focused on developing diverse effective treatments, driven by the rising prevalence of chronic diseases.

As clinical trials become more intricate, precise execution and diligent oversight of operations within research organizations are paramount. To mitigate errors stemming from improper execution, these organizations are increasingly outsourcing clinical trials to facilitate their product development. Clinical Research Organizations (CROs) are instrumental in successful trial implementation, offering services that leverage high-quality facilities and deep subject matter expertise. CROs have effectively become the backbone of the clinical trial industry through their efficient and cost-effective operations, providing substantial benefits to trial sponsors. Consequently, the advancement of cost-effective solutions and the reduction of errors by CROs during the drug development process are significant drivers of clinical trials market growth.

Download our Sample PDF Report

@ https://www.businessmarketinsights.com/sample/BMIRE00028989

Europe Clinical Trials Market Overview

The Europe clinical trials market encompasses the UK, Germany, France, Italy, Spain, and the Rest of Europe. The market in Europe is projected to expand during the forecast period, primarily due to an escalating number of clinical trial activities for new drug development and the introduction of innovative products by companies.

In Germany, frequently studied conditions in clinical trials include cancer, cardiovascular illness, nervous system disorders, and infectious diseases. Germany's well-developed infrastructure, including transport, communication, energy, and public services, provides a strong advantage for clinical research. Furthermore, the country benefits from a sizable patient pool and a high demand for quality healthcare. To boost academic clinical research, the Federal Ministry of Education and Research has established coordinating centers for clinical trials under a new funding program. Depending on the product under investigation, clinical trials in Germany receive approval from either the Federal Institute for Drugs and Medical Devices or the Paul-Ehrlich Institute.

Europe Clinical Trials Market Segmentation

Europe Clinical Trials Market By Study Design

Interventional

Observational

Expanded Access

Europe Clinical Trials Market By Phase

Phase I

Phase II

Phase III

Phase IV

Europe Clinical Trials Market By Indication

Autoimmune/Inflammation

Pain Management

Oncology

CNS Condition

Diabetes

Obesity

Cardiovascular

Europe Clinical Trials Market Regions and Countries Covered       

Europe

UK

Germany

France

Russia

Italy

Rest of Europe

Europe Clinical Trials Market leaders and key company profiles   

Charles River Laboratories InternationalInc

ICON Plc

IQVIA Holdings Inc

IXICO Plc

Laboratory Corp of America Holdings

Parexel International Corp

SGS SA

Syneos Health Inc

Thermo Fisher Scientific Inc

WuXi AppTec Co Ltd

About Us:

Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications